TickerFacts.

Pluri Inc. (PLUR): Cost of Revenue

Annual figures by period end, from SEC filings.

$563.0K
Year ended 2026-06-30
n/m
3-year compound annual growth
+18.9%
10-year compound annual growth
$682.0K2012-06-30: $21.0K2013-06-30: $20.0K2014-06-30: $11.0K2015-06-30: $13.0K2016-06-30: $100.0K2018-06-30: $2.0K2019-06-30: $2.0K2023-06-30: $9.0K2024-06-30: $4.0K2025-06-30: $682.0K2026-06-30: $563.0K$563.0K
2012-06-30 Cost of Revenue (USD) 2026-06-30
Period endedCost of RevenueChange YoYSource filing
2026-06-30$563.0K-17.4%2026-09-10, From 2025-07-01
2025-06-30$682.0Kn/m2026-09-10, From 2024-07-01
2024-06-30$4.0K-55.6%2025-09-17, From 2023-07-01
2023-06-30$9.0Kn/a2024-09-18, From 2022-07-01
No annual figure between 2019-06-30 and 2023-06-30.
2019-06-30$2.0K0.0%2020-09-10, From 2018-07-01
2018-06-30$2.0Kn/a2020-09-10, From 2017-07-01
No annual figure between 2016-06-30 and 2018-06-30.
2016-06-30$100.0K+669.2%2018-09-12, From 2015-07-01
2015-06-30$13.0K+18.2%2017-09-07, From 2014-07-01
2014-06-30$11.0K-45.0%2016-09-07, From 2013-07-01
2013-06-30$20.0K-4.8%2015-09-09, From 2012-07-01
2012-06-30$21.0Kn/a2014-09-11, From 2011-07-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Pluri Inc. (PLUR)2026-06-30$563.0K-17.4%
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$3.96M+220.1%
Outlook Therapeutics, Inc. (OTLK)2025-09-30$1.36Mn/a
Humacyte, Inc. (HUMA)2025-12-31$9.70Mn/a
Dyadic International Inc (DYAI)2025-12-31$2.32M+94.2%
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$931.0K+10.3%
VivoSim Labs, Inc. (VIVS)2026-03-31$0-100.0%
Alpha Cognition Inc. (ACOG)2025-12-31$603.4Kn/a
Pelthos Therapeutics Inc. (PTHS)2025-12-31$3.99Mn/a

Compare PLUR, SCNI, OTLK, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗